

# Amendment Tool

v1.6 06 December 2021

For office use

QC: No

## Section 1: Project information

Short project title*:	The RECOVERY Trial			
IRAS project ID* (or REC reference if no IRAS project ID is available):	281712			
Sponsor amendment reference number*:	Substantial Amendment 25			
Sponsor amendment date* (enter as DD/MM/YY):	10 March 2022			
Briefly summarise in lay language the main changes proposed in this amendment. Explain the purpose of the changes and their significance for the study. If the amendment significantly alters the research design or methodology, or could otherwise affect the scientific value of the study, supporting scientific information should be given (or enclosed separately). Indicate whether or not additional scientific critique has been obtained (note: this field will adapt to the amount of text entered)*:	Following discussions with the sponsor's insurer and MHRA it is necessary to exclude pregnant women in their first trimester from the Paxlovid comparison. We have also updated other sections of the protocol at MHRA's request. At the REC's request, we have also added information to the protocol and PIS about how information about outcomes of women pregnant at randomisation will be collected. We have also completed recruitment of children with PIMS-TS into the tocilizumab and anakinra comparisons so have removed those from the protocol. We also seek permission to request that participants discharged before day 5 are provided with a kit to take the day 5 swab at home and post it back to the trial laboratory. We have also added some additional safety outcomes that we wish to collect.			
Project type (select):	<b>Specific study</b>			
	Research tissue bank Research database			
Has the study been reviewed by a UKECA-recognised Research Ethics Committee (REC) prior to this amendment?:	<b>Yes</b>		No	
What type of UKECA-recognised Research Ethics Committee (REC) review is applicable? (select):	<b>NHS/HSC REC</b>			
	Ministry of Defence (MoDREC)			
Is all or part of this amendment being resubmitted to the Research Ethics Committee (REC) as a <b>modified amendment</b> (i.e. a substantial amendment previously given an unfavourable opinion)?	Yes		<b>No</b>	
Where is the NHS/HSC Research Ethics Committee (REC) that reviewed the study based?:	England	Wales	Scotland	Northern Ireland
	<b>Yes</b>	No	No	No
Was the study a clinical trial of an investigational medicinal product (CTIMP) OR does the amendment make it one?:	<b>Yes</b>		No	
EudraCT number*:	2020-001113-21			
Was this clinical trial of an investigational medicinal product (CTIMP) processed under the CTIMP combined review service (formerly known as the Combined Ways of Working (CWOW) pilot)?:	Yes		<b>No</b>	
Did the study receive Pharmacy Assurance?:	<b>Yes</b>		No	
Was the study a clinical investigation or other study of a medical device OR does the amendment make it one?:	Yes		<b>No</b>	
Did the study involve the administration of radioactive substances, therefore requiring ARSAC review, OR does the amendment introduce this?:	Yes		<b>No</b>	
Did the study involve the use of research exposures to ionising radiation (not involving the administration of radioactive substances) OR does the amendment introduce this?:	Yes		<b>No</b>	
Did the study involve adults lacking capacity OR does the amendment introduce this?:	<b>Yes</b>		No	
Did the study involve access to confidential patient information outside the direct care team without consent OR does the amendment introduce this?:	Yes		<b>No</b>	
Did the study involve prisoners or young offenders who are in custody or supervised by the probation service OR does the amendment introduce this?:	Yes		<b>No</b>	
Did the study involve children OR does the amendment introduce this?:	<b>Yes</b>		No	
Did the study involve NHS/HSC organisations prior to this amendment?:	<b>Yes</b>		No	
Did the study involve non-NHS/HSC organisations OR does the amendment introduce them?:	Yes		<b>No</b>	
	England	Wales	Scotland	Northern Ireland
Lead nation for the study:	<b>Yes</b>	No	No	No
Which nations had participating NHS/HSC organisations prior to this amendment?	<b>Yes</b>	<b>Yes</b>	<b>Yes</b>	<b>Yes</b>
Which nations will have participating NHS/HSC organisations after this amendment?	<b>Yes</b>	<b>Yes</b>	<b>Yes</b>	<b>Yes</b>

## Section 2: Summary of change(s)

What do you want to update?:	<b>Project information</b>
	New site/PI only

**Please note:** Each change being made as part of the amendment must be entered separately. For example, if an amendment to a clinical trial of an investigational medicinal product (CTIMP) involves an update to the Investigator's Brochure (IB), affecting the Reference Safety Information (RSI) and so the information documents to be given to participants, these should be entered into the Amendment Tool as three separate changes. A list of all possible changes is available on the "Glossary of Amendment Options" tab. To add another change, click the "Add another change" box.

Change 1				
Area of change (select)*:	Study Design			
Specific change (select - only available when area of change is selected first)*:	Inclusion/exclusion criteria - Significant change (e.g. to age range) likely to affect safety or scientific value of study			
Further information (free text - note that this field will adapt to the amount of text entered):	We have modified the protocol in the light of comments received from MHRA around inclusion of pregnant women and details of use of Paxlovid.			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	Yes	Yes	Yes	Yes
Will all participating NHS/HSC organisations be affected by this change, or only some? ( <b>please note</b> that this answer may affect the categorisation for the change):	All		Some	
				Remove all changes below

Change 2				
Area of change (select)*:	Study Design			
Specific change (select - only available when area of change is selected first)*:	Other minor change to study design that can be implemented within existing resource in place at participating organisations - Please specify in the free text below			
Further information In particular, please describe why this change can be implemented within the existing resource in place at the participating organisations (free text - note that this field will adapt to the amount of text entered)*	<p>Following review of SA24 by MHRA we have added clarification to the protocol around:</p> <p>(i) the eligibility assessment of and analysis of data from participants who may receive more than one trial treatment in the factorial design (now described in more detail on protocol page 1-2)</p> <p>(ii) how potential interacting medications are handled by site staff (described in protocol appendix 8.2)</p> <p>(iii) monitoring of participants after discharge and completion of course of Paxlovid at home.</p>			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	Yes	Yes	Yes	Yes
Will all participating NHS/HSC organisations be affected by this change, or only some? ( <b>please note</b> that this answer may affect the categorisation for the change):	All		Some	
				Remove all changes below

Change 3				
Area of change (select)*:	Participant Procedures			
Specific change (select - only available when area of change is selected first)*:	Participant procedures - minor change that can be implemented within existing resource at participating organisations - Please specify in the free text below			
Further information In particular, please describe why this change can be implemented within the existing resource in place at the participating organisations (free text - note that this field will adapt to the amount of text entered)*	Information added to protocol and PIS about method of collecting pregnancy outcome information using UK Obstetric Surveillance System.			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	Yes	Yes	Yes	Yes
Will all participating NHS/HSC organisations be affected by this change, or only some? ( <b>please note</b> that this answer may affect the categorisation for the change):	All		Some	
				Remove all changes below

Change 4				
Area of change (select)*:	CTIMP IMP			
Specific change (select - only available when area of change is selected first)*:	Change of IMPs			
Further information (free text - note that this field will adapt to the amount of text entered):	We have completed recruitment into the comparisons of tocilizumab and anakinra among children with PIMS-TS so wish to remove these from the protocol. We have updated the children's PIS/ICF accordingly.			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	Yes	Yes	Yes	Yes
Will all participating NHS/HSC organisations be affected by this change, or only some? ( <b>please note</b> that this answer may affect the categorisation for the change):	All		Some	
Remove all changes below				

Change 5				
Area of change (select)*:	Study Design			
Specific change (select - only available when area of change is selected first)*:	Samples - significant changes (e.g. to the arrangements for removal, storage or use of samples under the relevant legislation on Human Tissue)			
Further information (free text - note that this field will adapt to the amount of text entered):	As some participants are discharged before day 5 (when those in the antiviral comparisons would have a nasal swab taken) we wish to provide participants with instructions and materials to take this swab at home and post it back to the trial laboratory.			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	Yes	Yes	Yes	Yes
Will all participating NHS/HSC organisations be affected by this change, or only some? ( <b>please note</b> that this answer may affect the categorisation for the change):	All		Some	
Remove all changes below				

Change 6				
Area of change (select)*:	CTIMP safety			
Specific change (select - only available when area of change is selected first)*:	Study oversight - Additional monitoring, not part of an urgent safety measure, but taken on a precautionary basis			
Further information (free text - note that this field will adapt to the amount of text entered):	We wish to collect some additional safety information on all participants. This is not because of a specific concern.			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	Yes	Yes	Yes	Yes
Will all participating NHS/HSC organisations be affected by this change, or only some? ( <b>please note</b> that this answer may affect the categorisation for the change):	All		Some	
Remove all changes below				

Change 7				
Area of change (select)*:	Study Documents			
Specific change (select - only available when area of change is selected first)*:	Correction of typographical errors			
Further information (free text - note that this field will adapt to the amount of text entered):				
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	Yes	Yes	Yes	Yes
Will all participating NHS/HSC organisations be affected by this change, or only some? ( <b>please note</b> that this answer may affect the categorisation for the change):	All		Some	

**Section 3: Declaration(s) and lock for submission****Declaration by the Sponsor or authorised delegate**

- I confirm that the Sponsor takes responsibility for the completed amendment tool
- I confirm that I have been formally authorised by the Sponsor to complete the amendment tool on their behalf

<i>Applicant identification:</i>	<b>Sponsor</b>
	Legal representative of the sponsor Person or organisation authorised by the sponsor
<i>Organisation:</i>	University of Oxford
<i>Name [first name and surname]*:</i>	Elaine Chick
<i>Address:</i>	CTRG, Boundary Brook House, Churchill Drive, Headington, Oxford OX3 7GB
<i>Telephone number:</i>	
<i>Fax number:</i>	
<i>Purchase Order (PO) number for MHRA invoicing:</i>	H62017838
<i>Email address*:</i>	ctrg@admin.ox.ac.uk

**Lock for submission**

**Please note:** This button will only become available when all mandatory (\*) fields have been completed. When the button is available, clicking it will generate a locked PDF copy of the completed amendment tool which must be included in the amendment submission. Please ensure that the amendment tool is completed correctly before locking it for submission.

**Lock for submission**

After locking the tool, [proceed to submit the amendment online](#). The "Submission Guidance" tab provides further information about the next steps for the amendment.

**Section 4: Review bodies for the amendment**

**Please note:** This section is for **information only**. Details in this section will complete automatically based on the options selected in Sections 1 and 2.

	Review bodies																		Category
	UK wide:						England and Wales:				Scotland:				Northern Ireland:				
	REC	Competent Authority MHRA - Medicines	Competent Authority MHRA - Devices	ARSAC	Radiation Assurance	UKSW Governance	REC (MCA)	CAG	HMPPS	HRA and HCRW Approval	REC (AWIA)	PBPP	SPS (RAEC)	National coordinating function	HSC REC	HSC Data Guardians	Prisons	National coordinating function	
Change 1:	Y	Y				(Y)				(Y)				(Y)				(Y)	A
Change 2:	N	N				(Y)				(Y)				(Y)				(Y)	C
Change 3:	N	N				(Y)				(Y)				(Y)				(Y)	C
Change 4:	Y	Y				(Y)				(Y)				(Y)				(Y)	A
Change 5:	Y	N				Y				Y				Y				Y	A
Change 6:	N	N				(Y)				(Y)				(Y)				(Y)	A
Change 7:	N	N				N				N				N				N	N/A
Overall reviews for the amendment:																			
Full review:	Y	Y				Y				Y				Y				Y	
Notification only:	N	N				N				N				N				N	
Overall amendment type:	Substantial for review																		

Overall Category:	A
-------------------	---